نتایج جستجو برای: cytarabine

تعداد نتایج: 4434  

2010
Dae Hyoung Lee Nak Gyun Chung Bin Cho Hack Ki Kim Hyoung Jin Kang Hee Young Shin Hyo Seop Ahn Keon Hee Yoo Ki Woong Sung Hong Hoe Koo Hoon Kook Tai Ju Hwang Ho Joon Im Jong Jin Seo Hyeon Jin Park

We investigated the outcome of idarubicin plus N(4)-behenoyl-1-beta-D-arabinofuranosyl cytosine (BHAC)-based chemotherapy (BHAC group, n=149) compared to idarubicin plus cytarabine-based chemotherapy (cytarabine group, n=191) for childhood acute myeloid leukemia (AML). Between January 1996 and December 2005, 340 children with AML from 5 university hospitals in Korea received the BHAC-based or c...

2011
Xuelian Xu Chengzhi Xie Holly Edwards Hui Zhou Steven A. Buck Yubin Ge

BACKGROUND Pediatric acute myeloid leukemia (AML) remains a challenging disease to treat even with intensified cytarabine-based chemotherapy. Histone deacetylases (HDACs) have been reported to be promising therapeutic targets for treating AML. However, HDAC family members that are involved in chemotherapy sensitivities remain unknown. In this study, we sought to identify members of the HDAC fam...

2017
Jun Ma Xinyu Li Yongwei Su Jianyun Zhao Daniel A. Luedtke Valeria Epshteyn Holly Edwards Guan Wang Zhihong Wang Roland Chu Jeffrey W. Taub Hai Lin Yue Wang Yubin Ge

Acute myeloid leukemia (AML) continues to be a challenging disease to treat, thus new treatment strategies are needed. In this study, we investigated the antileukemic effects of ATR inhibition alone or combined with cytarabine in AML cells. Treatment with the ATR-selective inhibitor AZ20 caused proliferation inhibition in AML cell lines and primary patient samples. It partially abolished the G2...

Journal: :Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014
Roelof Willemze Stefan Suciu Giovanna Meloni Boris Labar Jean-Pierre Marie Constantijn J M Halkes Petra Muus Martin Mistrik Sergio Amadori Giorgina Specchia Francesco Fabbiano Francesco Nobile Marco Sborgia Andrea Camera Dominik L D Selleslag Francois Lefrère Domenico Magro Simona Sica Nicola Cantore Meral Beksac Zwi Berneman Xavier Thomas Lorella Melillo Jose E Guimaraes Pietro Leoni Mario Luppi Maria E Mitra Dominique Bron Georges Fillet Erik W A Marijt Adriano Venditti Anne Hagemeijer Marco Mancini Joop Jansen Daniela Cilloni Liv Meert Paola Fazi Marco Vignetti Silvia M Trisolini Franco Mandelli Theo de Witte

PURPOSE Cytarabine plays a pivotal role in the treatment of patients with acute myeloid leukemia (AML). Most centers use 7 to 10 days of cytarabine at a daily dose of 100 to 200 mg/m(2) for remission induction. Consensus has not been reached on the benefit of higher dosages of cytarabine. PATIENTS AND METHODS The European Organisation for Research and Treatment of Cancer (EORTC) and Gruppo It...

2017
Rino Sato Robert Park

Cytarabine (cytosine arabinoside, Ara-C) is an antimetabolite analogue of cytidine that is used as a chemotherapeutic agent for the treatment of acute myelogenous leukemia and lymphocytic leukemias . The most common side effects of this therapy include myelosuppression, pancytopenia, hepatotoxicity, gastrointestinal ulceration with bleeding, and pulmonary infiltrates. Cardio-pulmonary complicat...

2017
Phu Ngoc Tran Xiao-Tang Kong

Acute cerebellar syndrome can be caused by high doses of cytarabine, but it has not been described in patients with acute lymphoblastic leukemia (ALL) who received hyper-CVAD chemotherapy. Herein, we report two cases with histories of positive Philadelphia chromosome B-cell ALL who developed acute cerebellar syndrome after the exposure to relatively low doses of cytarabine in the second cycle o...

Journal: :Nucleic acids research 1998
W H Gmeiner A Skradis R T Pon J Liu

Cytarabine is a potent anticancer drug that interferes with elongation of the lagging strand at the replication fork during DNA synthesis. The effects of cytarabine substitution on the structural and thermodynamic properties of a model Okazaki fragment were investigated using UV hyperchromicity and 1H NMR spectroscopy to determine how cytarabine alters the physicochemical properties of Okazaki ...

Journal: :Blood 2012
Thomas Pabst Edo Vellenga Wim van Putten Harry C Schouten Carlos Graux Marie-Christiane Vekemans Bart Biemond Peter Sonneveld Jakob Passweg Leo Verdonck Marie-Cecile Legdeur Matthias Theobald Emanuel Jacky Mario Bargetzi Johan Maertens Gert Jan Ossenkoppele Bob Löwenberg

The clinical value of chemotherapy sensitization of acute myeloid leukemia (AML) with G-CSF priming has remained controversial. Cytarabine is a key constituent of remission induction chemotherapy. The effect of G-CSF priming has not been investigated in relationship with variable dose levels of cytarabine. We randomized 917 AML patients to receive G-CSF (456 patients) or no G-CSF (461 patients)...

2015
Linu A. Jacob S. Aparna K. C. Lakshmaiah D. Lokanatha Govind Babu Suresh Babu Sandhya Appachu

Introduction. The incidence of Acute Myeloid Leukemia (AML) increases progressively with age and its treatment is challenging. This prospective case control study was undertaken to compare the safety, efficacy, and cost-effectiveness of decitabine with those of cytarabine in older patients with newly diagnosed AML who are not fit for intensive chemotherapy. Materials and Methods. 30 eligible pa...

Journal: :International Journal of Oncology 2021

Acute myeloid leukemia (AML) is a complex hematological disorder characterized by blockage of differentiation and high proliferation rates progenitors. Anthracycline cytarabine‑based therapy has remained the standard treatment for AML over last four decades. Although this strategy increased survival rates, patients often develop resistance to these drugs. Despite efforts understand mechanisms u...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید